Literature DB >> 20682457

Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence.

Arthur L Brody1, Edythe D London, Richard E Olmstead, Zoe Allen-Martinez, Stephanie Shulenberger, Matthew R Costello, Anna L Abrams, David Scheibal, Judah Farahi, Steven Shoptaw, Mark A Mandelkern.   

Abstract

The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n=14), bupropion HCl (n=14), or matching pill placebo (n=15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced (11)C-raclopride binding potential (BP(ND)) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP(ND) after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dose-dependent, and is not significantly affected by reductions in daily smoking levels or treatment type. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682457      PMCID: PMC2947623          DOI: 10.1016/j.pscychresns.2009.06.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  67 in total

Review 1.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

2.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.

Authors:  F E Pontieri; G Tanda; F Orzi; G Di Chiara
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

5.  Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens.

Authors:  G Damsma; J Day; H C Fibiger
Journal:  Eur J Pharmacol       Date:  1989-09-22       Impact factor: 4.432

6.  Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum.

Authors:  O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

Review 7.  Neuroimaging and the functional neuroanatomy of psychotherapy.

Authors:  Joshua L Roffman; Carl D Marci; Debra M Glick; Darin D Dougherty; Scott L Rauch
Journal:  Psychol Med       Date:  2005-10       Impact factor: 7.723

8.  PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects.

Authors:  T E Schlaepfer; G D Pearlson; D F Wong; S Marenco; R F Dannals
Journal:  Am J Psychiatry       Date:  1997-09       Impact factor: 18.112

9.  Psychological mediators of bupropion sustained-release treatment for smoking cessation.

Authors:  Danielle E McCarthy; Thomas M Piasecki; Daniel L Lawrence; Douglas E Jorenby; Saul Shiffman; Timothy B Baker
Journal:  Addiction       Date:  2008-09       Impact factor: 6.526

Review 10.  Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals.

Authors:  Susanne Nikolaus; Rolf Larisch; Markus Beu; Christina Antke; Konstantin Kley; Farhad Forutan; Andreas Wirrwar; Hans-Wilhelm Müller
Journal:  Rev Neurosci       Date:  2007       Impact factor: 4.353

View more
  19 in total

1.  Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans.

Authors:  Bernard Le Foll; Mihail Guranda; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Victoria C Wing; Laurie Zawertailo; Usoa Busto; Peter Selby; Arthur L Brody; Tony P George; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2013-08-19       Impact factor: 7.853

2.  A preliminary study of the neural effects of behavioral therapy for substance use disorders.

Authors:  Elise E DeVito; Patrick D Worhunsky; Kathleen M Carroll; Bruce J Rounsaville; Hedy Kober; Marc N Potenza
Journal:  Drug Alcohol Depend       Date:  2011-10-29       Impact factor: 4.492

Review 3.  Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; David Shurtleff
Journal:  Mol Neurobiol       Date:  2011-07-01       Impact factor: 5.590

Review 4.  A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate.

Authors:  Thulasi Thiruchselvam; Saima Malik; Bernard Le Foll
Journal:  Am J Drug Alcohol Abuse       Date:  2016-11-30       Impact factor: 3.829

Review 5.  Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans.

Authors:  Agnes J Jasinska; Todd Zorick; Arthur L Brody; Elliot A Stein
Journal:  Neuropharmacology       Date:  2013-03-06       Impact factor: 5.250

6.  Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.

Authors:  Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary
Journal:  Nicotine Tob Res       Date:  2016-08-03       Impact factor: 4.244

7.  Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats.

Authors:  Matthew R Costello; Daisy D Reynaga; Celina Y Mojica; Nurulain T Zaveri; James D Belluzzi; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2014-02-11       Impact factor: 7.853

Review 8.  Common and distinct neural targets of treatment: changing brain function in substance addiction.

Authors:  Anna B Konova; Scott J Moeller; Rita Z Goldstein
Journal:  Neurosci Biobehav Rev       Date:  2013-10-16       Impact factor: 8.989

9.  Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study.

Authors:  Patricia Di Ciano; Mihail Guranda; Dina Lagzdins; Rachel F Tyndale; Islam Gamaleddin; Peter Selby; Isabelle Boileau; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2015-10-07       Impact factor: 7.853

10.  Limitations of SRTM, Logan graphical method, and equilibrium analysis for measuring transient dopamine release with [(11)C]raclopride PET.

Authors:  Jenna M Sullivan; Su Jin Kim; Kelly P Cosgrove; Evan D Morris
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.